Candidate target genes were evaluated by assessing each CCV’s potential impact on regulatory or coding features using a computational pipeline, INtegrated expression QUantitative trait and In SIlico prediction of GWAS Targets (INQUISIT)35,54. Briefly, genes were considered as potential targets of candidate causal variants through effects on: (1) distal gene regulation, (2) proximal regulation, or (3) a gene’s coding sequence. We intersected CCV positions with multiple sources of genomic information chromatin interaction analysis by paired-end tag sequencing (ChIA-PET79) in MCF7 cells and genome-wide chromosome conformation capture (Hi-C) in HMECs. We used breast cell line computational enhancer–promoter correlations (PreSTIGE80, IM-PET81, FANTOM582) breast cell super-enhancer83, breast tissue-specific expression variants (eQTL) from multiple independent studies (TCGA (normal breast and breast tumour) and GTEx breast—see eQTL methods), transcription factor and histone modification chromatin immunoprecipitation followed by sequencing (ChIP-seq) from the ENCODE and Roadmap Epigenomics Projects together with the genomic features found to be significantly enriched for all known breast cancer CCVs54, gene expression RNA-seq from several breast cancer lines and normal samples (ENCODE) and topologically associated domain (TAD) boundaries from T47D cells (ENCODE84). To assess the impact of intragenic variants, we evaluated their potential to alter primary protein coding sequence and splicing using Ensembl Variant Effect Predictor85 using MaxEntScan and dbscSNV modules for splicing alterations based on ada and rf scores. Nonsense and missense changes were assessed with the REVEL ensemble algorithm, with CCVs displaying REVEL scores >0.5 deemed deleterious.

Each target gene prediction category (distal, promoter or coding) was scored according to different criteria. Genes predicted to be distally regulated targets of CCVs were awarded points based on physical links (for example ChIA-PET), computational prediction methods, or eQTL associations. All CCVs were considered as potentially involved in distal regulation. Intersection of a putative distal enhancer with genomic features found to be significantly enriched54 were further upweighted. Multiple independent interactions were awarded an additional point. CCVs in gene proximal regulatory regions were intersected with histone ChIP-Seq peaks characteristic of promoters and assigned to the overlapping transcription start sites (defined as −1.0 kb – +0.1 kb). Further points were awarded to such genes if there was evidence for eQTL association, while a lack of expression resulted in down-weighting as potential targets. Potential coding changes including missense, nonsense and predicted splicing alterations resulted in addition of one point to the encoded gene for each type of change, while lack of expression reduced the score. We added an additional point for predicted target genes that were also breast cancer drivers (278 genes35,54). For each category, scores potentially ranged from 0 to 8 (distal); 0 to 4 (promoter) or 0 to 3 (coding). We converted these scores into ‘confidence levels’: Level 1 (highest confidence) when distal score > 4, promoter score ≥3 or coding score >1; Level 2 when distal score ≤ 4 and ≥1, promoter score = 1 or = 2, coding score = 1; and Level 3 when distal score <1 and >0, promoter score <1 and >0, and coding <1 and >0. For genes with multiple scores (for example, predicted as targets from multiple independent risk signals or predicted to be impacted in several categories), we recorded the highest score.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.